Literature DB >> 28729467

STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance.

Praveena S Thiagarajan1,2, Qiao Zheng1, Manvir Bhagrath1, Erin E Mulkearns-Hubert1, Martin G Myers3, Justin D Lathia4,2,5, Ofer Reizes4,2,5.   

Abstract

Leptin (LEP) binds to the long form of the leptin receptor (LEPRb), leading to the activation of multiple signaling pathways that are potential targets for disrupting the obesity-breast cancer link. In triple-negative breast cancer (TNBC), LEP is hypothesized to predominantly mediate its tumorigenic effects via a subpopulation of LEPRb-positive tumor cells termed cancer stem cells (CSCs) that can initiate tumors and induce tumor progression. Previously, we showed that LEP promotes CSC survival in vivo Moreover, silencing LEPRb in TNBC cells compromised the CSC state. The mechanisms by which LEPRb regulates TNBC CSC intracellular signaling are not clear. We hypothesized that activation of LEPRb signaling is sufficient to drive CSC maintenance in TNBC. Here, we show that activation of LEPRb in non-CSCs isolated using our CSC reporter system resulted in a transition to the stem cell state. In CSCs, LEP induced STAT3 phosphorylation, whereas LEP did not induce STAT3 phosphorylation in non-CSCs. Introduction of constitutively active STAT3 into LEPRb-transfected non-CSCs significantly induced NANOG, SOX2 and OCT4 expression compared with control non-CSCs. To determine the intracellular phospho-tyrosine residue of LEPRb that is necessary for the induction of the stem cell state in non-CSCs, we transfected the tyrosine residue point mutants L985, F1077 and S1138 into non-CSCs. Non-CSCs transfected with the L985 mutant exhibited increased STAT3 phosphorylation, increased SOCS3 expression and an induction of GFP expression compared with non-CSCs expressing the F1077 and S1138 mutants. Our data demonstrate that LEPRb-induced STAT3 activation is essential for the induction and maintenance of TNBC CSCs.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  breast; carcinoma; leptin; receptors

Mesh:

Substances:

Year:  2017        PMID: 28729467      PMCID: PMC5551450          DOI: 10.1530/ERC-16-0349

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  40 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Authors:  Michael O Idowu; Maciej Kmieciak; Catherine Dumur; Regina S Burton; Margaret M Grimes; Celeste N Powers; Masoud H Manjili
Journal:  Hum Pathol       Date:  2011-08-10       Impact factor: 3.466

3.  Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.

Authors:  Ines Barone; Stefania Catalano; Luca Gelsomino; Stefania Marsico; Cinzia Giordano; Salvatore Panza; Daniela Bonofiglio; Gianluca Bossi; Kyle R Covington; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 5.  Obesity and cancer.

Authors:  Eugenia E Calle; Michael J Thun
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

6.  Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.

Authors:  Diego de Mendonça Uchôa; Marcia Silveira Graudenz; Sidia Maria Callegari-Jacques; Carolina Rigatti Hartmann; Bruna Pellini Ferreira; Mariana Fitarelli-Kiehl; Maria Isabel Edelweiss
Journal:  Pathol Res Pract       Date:  2014-03-27       Impact factor: 3.250

7.  SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985.

Authors:  C Bjorbak; H J Lavery; S H Bates; R K Olson; S M Davis; J S Flier; M G Myers
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

8.  Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma.

Authors:  Kaouther Snoussi; A Donny Strosberg; Noureddine Bouaouina; Slim Ben Ahmed; A Noureddine Helal; Lotfi Chouchane
Journal:  BMC Cancer       Date:  2006-02-20       Impact factor: 4.430

Review 9.  Leptin receptor signaling and the regulation of mammalian physiology.

Authors:  Martin G Myers
Journal:  Recent Prog Horm Res       Date:  2004

10.  Leptin receptor expression and cell signaling in breast cancer.

Authors:  Krista A Frankenberry; Heath Skinner; Ponnandai Somasundar; David W McFadden; Linda C Vona-Davis
Journal:  Int J Oncol       Date:  2006-04       Impact factor: 5.650

View more
  18 in total

1.  Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling.

Authors:  Yawen Li; Ronghua Wang; Si Xiong; Xiju Wang; Zhenxiong Zhao; Shuya Bai; Yun Wang; Yuchong Zhao; Bin Cheng
Journal:  J Mol Med (Berl)       Date:  2018-12-18       Impact factor: 4.599

Review 2.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

Review 3.  The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis.

Authors:  Aneesha Kulkarni; Laura W Bowers
Journal:  Cell Mol Life Sci       Date:  2021-01-19       Impact factor: 9.261

4.  Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.

Authors:  Kuo Chen; Jin Zhang; Narasimha M Beeraka; Chengyun Tang; Yulia V Babayeva; Mikhail Y Sinelnikov; Xinliang Zhang; Jiacheng Zhang; Junqi Liu; Igor V Reshetov; Olga A Sukocheva; Pengwei Lu; Ruitai Fan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

5.  KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.

Authors:  Mei Zhou; Prabhakar Pitta Venkata; Suryavathi Viswanadhapalli; Bridgitte Palacios; Salvador Alejo; Yihong Chen; Yi He; Uday P Pratap; Junhao Liu; Yi Zou; Zhao Lai; Takayoshi Suzuki; Andrew J Brenner; Rajeshwar R Tekmal; Ratna K Vadlamudi; Gangadhara R Sareddy
Journal:  Breast Cancer Res Treat       Date:  2020-10-14       Impact factor: 4.872

6.  Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.

Authors:  Laura W Bowers; Emily L Rossi; Shannon B McDonell; Steven S Doerstling; Subreen A Khatib; Claire G Lineberger; Jody E Albright; Xiaohu Tang; Linda A deGraffenried; Stephen D Hursting
Journal:  Mol Cancer Res       Date:  2018-02-16       Impact factor: 5.852

7.  Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.

Authors:  Xiaocong Xiang; Li Deng; Rong Xiong; Dongqin Xiao; Zhu Chen; Fei Yang; Kang Liu; Gang Feng
Journal:  Cell Cycle       Date:  2018-07-25       Impact factor: 4.534

8.  Co-culturing polarized M2 Thp-1-derived macrophages enhance stemness of lung adenocarcinoma A549 cells.

Authors:  Xiaocheng Zhang; Mingyang Zhu; Zipu Hong; Chengshui Chen
Journal:  Ann Transl Med       Date:  2021-04

9.  Leptin and Notch Signaling Cooperate in Sustaining Glioblastoma Multiforme Progression.

Authors:  Salvatore Panza; Umberto Russo; Francesca Giordano; Antonella Leggio; Ines Barone; Daniela Bonofiglio; Luca Gelsomino; Rocco Malivindi; Francesca Luisa Conforti; Giuseppina Daniela Naimo; Cinzia Giordano; Stefania Catalano; Sebastiano Andò
Journal:  Biomolecules       Date:  2020-06-09

Review 10.  STAT3, stem cells, cancer stem cells and p63.

Authors:  Michaela Galoczova; Philip Coates; Borivoj Vojtesek
Journal:  Cell Mol Biol Lett       Date:  2018-03-22       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.